期刊
VACCINE
卷 27, 期 29, 页码 3811-3820出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.04.054
关键词
Influenza; Vaccine; Adjuvant
资金
- MAID [1 U01 A1074512-1]
Safe and effective adjuvants for influenza vaccines that Could increase both the levels of neutralizing antibody, including against drifted viral subtypes, and T-cell immunity Would be a major advance in vaccine design. The JVRS-100 adjuvant, consisting of DOTIM/cholesterol cationic liposome-DNA complexes, is particularly promising for vaccines that require induction Of high levels of antibody and T-cell immunity, including CD8(+) cytotoxic T lymphocytes (CTL). Inclusion of protein antigens with JVRS-100 results in the induction of enhanced humoral and cell-mediated (i.e., CD4(+) and CD8(+) T cells) immune responses. The JVRS-100 adjuvant combined with a split trivalent influenza vaccine (Fluzone (R)-sanofi pasteur) elicited increased antibody and T-cell responses in mice and non-human primates compared to vaccination with Fluzone (R) alone. Mice vaccinated with JVRS-100-Fluzone (R) and challenged with antigenically drifted strains of H1N1 (PR/8/34) and influenza B (B/Lee/40) Viruses had higher grade protection, as measured by attenuation of weight loss and increased Survival, compared to recipients of unadjuvanted vaccine. The results indicate that the JVRS-100 adjuvant substantially increases immunogenicity and protection from drifted-strain challenge using an existing influenza vaccine. (C) 2009 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据